BioCentury
ARTICLE | Clinical News

Novartis reports NAVIGATOR data

March 16, 2010 1:36 AM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) reported data from the Phase III NAVIGATOR trial of once-daily Diovan valsartan and thrice-daily Starlix nateglinide to delay progression to Type II diabetes in patients with impaired glucose tolerance and cardiovascular disease or risk factors. Diovan met the co-primary endpoint of significantly reducing the cumulative incidence of diabetes vs. placebo (33.1% vs. 36.8%, p<0.001). However, Diovan missed the co-primary endpoints of significantly reducing the incidence of core and extended cardiovascular outcomes vs. placebo. Starlix missed the three endpoints vs. placebo. The prospective, double-blind, placebo-controlled, international trial enrolled 9,306 patients. ...